Chemical formula: C₃₆H₅₃N₇O₆ Molecular mass: 679.863 g/mol PubChem compound: 24794466
Difelikefalin is a selective kappa opioid receptor agonist with low central nervous system penetration. The pathophysiology of chronic kidney disease-associated pruritus is thought to be multifactorial, including systemic inflammation and an imbalance in the endogenous opioid system (e.g., overexpression of mu opioid receptors and concomitant downregulation of kappa opioid receptors). The activation of kappa opioid receptors on peripheral sensory neurons and immune cells by difelikefalin are considered mechanistically responsible for the antipruritic and anti-inflammatory effects.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| V03AX04 | V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AX Other therapeutic products | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| KAPRUVIA Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Difelikefalin is an active ingredient of these brands:
Austria (AT)
Croatia (HR)
Estonia (EE)
France (FR)
Ireland (IE)
Israel (IL)
Italy (IT)
Lithuania (LT)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
